Breast, colon, prostate, and lung cancers did not stop for COVID-19 in 2020, but screenings and treatments did. Dramatically. The result, say doctors, could be a catastrophe in the making.
BridgeBio Pharma announced the launch of CoA Therapeutics, a biopharmaceutical company developing novel small-molecules designed to increase Coenzyme-A (CoA) levels in genetic disorders where CoA deficiency is implicated.